Olmesartán Stada (Olmesartan Medoxomil)

Olmesartan Medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy (as an adjunct): slows progression of kidney damage associated with diabetes.
• Heart failure (off‑label in some regions): may improve symptoms when combined with other heart‑failure therapies.
• Stroke prevention (off‑label): contributes to secondary prevention by controlling hypertension.
• Chronic kidney disease (off‑label): assists in blood‑pressure management to protect renal function.

• Olmesartan Medoxomil is a prodrug that is rapidly converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Olmesartan Medoxomil is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Upper respiratory tract infection

Serious or Rare Side Effects

• Angio‑edema (swelling of face, lips, tongue)
• Hyperkalemia (elevated blood potassium)
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevations
• Allergic skin reactions (e.g., rash, Stevens‑Johnson syndrome)

When prescribing Olmesartan Medoxomil, clinicians should consider several safety aspects.

• Renal function monitoring: assess baseline creatinine and eGFR, then periodically.
• Electrolyte assessment: check serum potassium, especially if combined with potassium‑sparing diuretics.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Concomitant NSAIDs: use caution as they may reduce antihypertensive effect and affect renal function.
• Hypotension risk: monitor blood pressure after initiation, particularly in volume‑depleted patients.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): heightened risk of kidney injury and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt blood‑pressure reduction and affect renal function.
• Lithium: may increase serum lithium levels, risking toxicity.
• Cyclosporine or tacrolimus: can raise olmesartan concentrations and affect kidney function.
• Diuretics: may enhance hypotensive effect, requiring dose adjustment.
• Rifampin: may reduce olmesartan plasma levels, diminishing antihypertensive effect.